IRMD
IRadimed Corporation
IRMD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IRMD overall, supported by stronger fundamentals and stronger valuation.
IRMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IRMD's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 32x | $59.44 | -30% |
| Forward | 36x | $85.23 | — |
| Fair | 41x | $76.32 | -10% |
| Current | 46x | $85.23 | — |
| Expensive | 71x | $133 | +57% |
Historical ranges are pointers, not guarantees.
IRMD's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 36x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over IRMD in the historical PE scenario, which offers more potential upside but is not a forecast.
IRMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IRMD, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +28% |
| Q3 2026 | $1.87 | +13% |
| Q2 2026 | $1.79 | +10% |
| Q1 2026 | $1.83 | +18% |
| Q4 2025 | $1.75 | +17% |
| Q3 2025 | $1.65 | +14% |
| Q2 2025 | $1.62 | +12% |
| Q1 2025 | $1.55 | +11% |
| Q4 2024 | $1.50 | +11% |
IRMD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
IRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2M | +14% |
| Q2 2026 | $20.5M | +0.3% |
| Q1 2026 | $22M | +13% |
| Q4 2025 | $22.7M | +17% |
| Q3 2025 | $21.2M | +16% |
| Q2 2025 | $20.4M | +14% |
| Q1 2025 | $19.5M | +11% |
| Q4 2024 | $19.4M | +11% |
IRMD's revenue has grown year over year for 23 quarters in a row: $24M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +1.4 points |
| Q2 2026 | 31% | -2 points |
| Q1 2026 | 33% | +5.1 points |
| Q4 2025 | 31% | +1.4 points |
| Q3 2025 | 32% | +0.6 points |
| Q2 2025 | 33% | +1.9 points |
| Q1 2025 | 28% | +0.9 points |
| Q4 2024 | 30% | +0.3 points |
IRMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IRMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
IRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +17% |
| Q2 2026 | $5.8M | +13% |
| Q1 2026 | $7.9M | +1226% |
| Q4 2025 | $5.6M | +76% |
| Q3 2025 | $5.8M | +10% |
| Q2 2025 | $5.1M | -7.2% |
| Q1 2025 | $594.6K | -84% |
| Q4 2024 | $3.2M | -5.4% |
IRMD generated $26M in free cash flow over the past year, up 77% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IRMD on cash flow, with more consistent year-over-year improvement.
IRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +4K shares |
| 1 year | +0.1% | +15.9K shares |
| 3 years | +1.1% | +140K shares |
| 5 years | +2.2% | +272K shares |
| Available history | +4.9% | +600K shares |
IRMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.2x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
IRMD has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over IRMD on leverage, with a lower net debt burden relative to earnings.
IRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 36.0 | Neutral |
IRMD's weekly RSI is 47 (neutral) and its Stochastic is 36 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IRMD PE vs Healthcare Sector
| Metric | IRMD | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 76% above |
| PE % | 60 | 29 | 31 pts above |
IRMD is trading at 46x earnings, a 76% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over IRMD on valuation relative to its sector.
IRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.1 | 0.1% above |
| 20 week MA | $88.2 | 3.3% below |
| 50 week MA | $92.6 | 8% below |
| 100 week MA | $77.7 | 9.7% above |
| 200 week MA | $61.2 | 39% above |
IRMD's trend is mixed: it's above three of its five weekly moving averages, and 39% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IRMD on trend strength, trading above more of its moving averages.
IRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.6 | $23.3 | -5.3% |
| 2021 | $23.3 | $45.9 | +97% |
| 2022 | $45.9 | $28.0 | -39% |
| 2023 | $28.0 | $47.5 | +70% |
| 2024 | $47.5 | $54.7 | +15% |
| 2025 | $54.7 | $97.5 | +78% |
| 2026 YTD | $97.5 | $85.2 | -13% |
IRMD has finished higher in four of the last six years, three of them by more than 50%. It's down 13% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IRMD on returns for 2026, with the stronger performance.